Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor in the Treatment of Mild Cognitive Impairment in Parkinson's disease
CAMBRIDGE - Sage Therapeutics, Inc. announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor in people with...
United Kingdom Ashley Kaplowitz Barry Greene Matthew Henson Sage Therapeutics Inc Wechsler Adult Intelligence Scale Fourth
Source: marketscreener.com